Clinical Trials in Peterborough, United Kingdom
16 recruiting
Showing 1–19 of 19 trials
Recruiting
Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Breast Cancer (Early Breast Cancer)
AstraZeneca4,300 enrolled711 locationsNCT05774951
Recruiting
Phase 3
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Janssen Research & Development, LLC600 enrolled69 locationsNCT07438496
Recruiting
Phase 3
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
Chronic Spontaneous Urticaria
Novartis Pharmaceuticals100 enrolled65 locationsNCT05677451
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche350 enrolled199 locationsNCT06588855
Recruiting
Not Applicable
WithHolding Enteral Feeds Around Blood Transfusion (International)
Necrotizing Enterocolitis
IWK Health Centre4,333 enrolled40 locationsNCT05213806
Recruiting
Phase 3
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
Obesity and Overweight
Metsera, a wholly owned subsidiary of Pfizer3,500 enrolled196 locationsNCT07311850
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,980 enrolled173 locationsNCT07321886
Recruiting
Phase 3
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
ObesityOverweightType 2 Diabetes+2 more
Pfizer999 enrolled184 locationsNCT07400653
Recruiting
Phase 3
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
Heart FailureSystemic Inflammation
Novo Nordisk A/S680 enrolled240 locationsNCT06200207
Recruiting
Phase 3
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
Influenza
ModernaTX, Inc.4,000 enrolled36 locationsNCT07496450
Recruiting
Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Atrial Fibrillation (AF)
Anthos Therapeutics, Inc.1,900 enrolled734 locationsNCT05712200
Recruiting
Phase 3
Early Vasopressors in Sepsis
Sepsis
NHS Greater Glasgow and Clyde1,006 enrolled25 locationsNCT05179499
Recruiting
DELIVER Study in a Population With Clinical Suspicion of Liver Cirrhosis
Cirrhosis, Liver
Owlstone Ltd240 enrolled4 locationsNCT07035158
Recruiting
UK Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction (HFpEF)
Manchester University NHS Foundation Trust10,000 enrolled26 locationsNCT05441839
Recruiting
Phase 3
Personalized Medicine for Advanced Biliary Cancer Patients
Biliary Tract Neoplasms
UNICANCER800 enrolled69 locationsNCT05615818
Recruiting
Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR)
Giant Cell ArteritisPolymyalgia Rheumatica
University of Leeds4,500 enrolled76 locationsNCT04102930
Recruiting
Phase 2
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
HER2-negative Breast CancerER+ Breast Cancer
Royal Marsden NHS Foundation Trust1,100 enrolled49 locationsNCT04985266
Recruiting
Phase 3
A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Lung Cancer, Nonsmall Cell
Imperial College London1,750 enrolled37 locationsNCT05085028
Recruiting
Phase 2Phase 3
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
Breast Cancer
Cambridge University Hospitals NHS Foundation Trust780 enrolled30 locationsNCT03150576